IL134896A0 - Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site - Google Patents

Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site

Info

Publication number
IL134896A0
IL134896A0 IL13489698A IL13489698A IL134896A0 IL 134896 A0 IL134896 A0 IL 134896A0 IL 13489698 A IL13489698 A IL 13489698A IL 13489698 A IL13489698 A IL 13489698A IL 134896 A0 IL134896 A0 IL 134896A0
Authority
IL
Israel
Prior art keywords
functional splice
site
retroviral
vector
functional
Prior art date
Application number
IL13489698A
Other languages
English (en)
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Publication of IL134896A0 publication Critical patent/IL134896A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cleaning Implements For Floors, Carpets, Furniture, Walls, And The Like (AREA)
  • Mattresses And Other Support Structures For Chairs And Beds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL13489698A 1997-09-25 1998-09-23 Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site IL134896A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9720465.5A GB9720465D0 (en) 1997-09-25 1997-09-25 Dual-virus vectors
PCT/GB1998/002867 WO1999015683A1 (fr) 1997-09-25 1998-09-23 Vecteurs retroviraux comprenant un site donneur d'epissage fonctionnel et un site accepteur d'epissage fonctionnel

Publications (1)

Publication Number Publication Date
IL134896A0 true IL134896A0 (en) 2001-05-20

Family

ID=10819668

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13489698A IL134896A0 (en) 1997-09-25 1998-09-23 Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site

Country Status (14)

Country Link
US (2) US6808922B1 (fr)
EP (1) EP1017837B1 (fr)
JP (1) JP2001517452A (fr)
KR (1) KR20010052077A (fr)
CN (1) CN1203183C (fr)
AT (1) ATE299189T1 (fr)
AU (1) AU750110B2 (fr)
CA (1) CA2304259A1 (fr)
DE (1) DE69830798T2 (fr)
GB (1) GB9720465D0 (fr)
IL (1) IL134896A0 (fr)
NO (1) NO20001486L (fr)
NZ (1) NZ503317A (fr)
WO (1) WO1999015683A1 (fr)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
ES2373406T3 (es) * 1997-12-22 2012-02-03 Oxford Biomedica (Uk) Limited Vectores basados en el virus de la anemia infecciosa equina (vaie).
GB2356200B (en) * 1997-12-22 2002-05-01 Oxford Biomedica Ltd Retroviral vectors
US7148035B1 (en) 1998-11-18 2006-12-12 Oxford Biomedica (Uk) Limited Polypeptide
EP1036091B2 (fr) 1998-11-18 2008-03-26 Oxford Biomedica (UK) Limited Antigene associe a la tumeur 5t4 pour une utilisation en immunotherapie anti-tumeur
GB0400443D0 (en) 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
GB9906615D0 (en) * 1999-03-22 1999-05-19 Oxford Biomedica Ltd Vector
WO2000078987A1 (fr) 1999-06-22 2000-12-28 Dnavec Research Inc. Vecteur d'expression de deux genes etrangers
CN1321182C (zh) * 1999-12-30 2007-06-13 卫生部艾滋病预防与控制中心 马传染性贫血病毒代表毒株的全基因克隆及其应用
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
GB0024550D0 (fr) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US6573092B1 (en) * 2000-10-10 2003-06-03 Genvec, Inc. Method of preparing a eukaryotic viral vector
CA2344208A1 (fr) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Methode
EP1504108B1 (fr) 2002-02-01 2013-04-17 Oxford Biomedica (UK) Limited Vecteur lentivirale
GB0203419D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
GB0203420D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
MX2007010306A (es) * 2005-02-23 2007-09-26 Uab Research Foundation Vacunacion mejorada con alquil-glicosido.
EP2045268B1 (fr) 2005-05-13 2011-09-21 Oxford BioMedica (UK) Limited Antigène peptide mhc classe I et II dérivé d'une tumeur antigène 5t4
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
US8377691B2 (en) * 2006-01-26 2013-02-19 Integral Molecular, Inc. Lipoparticles comprising ion channels, methods of making and using the same
WO2007089780A2 (fr) * 2006-01-30 2007-08-09 Licentia, Ltd. Matériaux de thérapie gènique à tyrosine kinase bmx/etk et méthodes
PL2307551T3 (pl) 2008-06-18 2017-07-31 Oxford Biomedica (Uk) Limited Oczyszczanie wektorów retrowirusowych
CN102946907A (zh) 2010-05-28 2013-02-27 牛津生物医学（英国）有限公司 慢病毒载体向脑的递送
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
DK2931897T3 (en) 2012-12-12 2018-02-05 Broad Inst Inc CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
EP2931899A1 (fr) 2012-12-12 2015-10-21 The Broad Institute, Inc. Génomique fonctionnelle employant des systèmes crispr-cas, des compositions, des procédés, des banques d'inactivation et leurs applications
CA2909733C (fr) * 2013-04-18 2023-10-17 Fondazione Telethon Administration efficace de grands genes par des vecteurs aav doubles
KR20160019553A (ko) 2013-06-17 2016-02-19 더 브로드 인스티튜트, 인코퍼레이티드 유사분열 후 세포의 질병 및 장애를 표적화하고 모델링하기 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
MX2015017312A (es) 2013-06-17 2017-04-10 Broad Inst Inc Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas.
KR20250012194A (ko) 2013-06-17 2025-01-23 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
WO2015053398A1 (fr) * 2013-10-11 2015-04-16 タカラバイオ株式会社 Vecteur rétroviral de titre élevé
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
WO2015077717A1 (fr) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions et méthodes pour diagnostiquer, évaluer et traiter un cancer au moyen d'un état de méthylation d'adn
WO2015085147A1 (fr) 2013-12-05 2015-06-11 The Broad Institute Inc. Typage de gènes polymorphes et détection de changements somatiques à l'aide de données de séquençage
MX2016007325A (es) 2013-12-12 2017-07-19 Broad Inst Inc Composiciones y metodos de uso de sistemas crispr-cas en desordenes debidos a repeticion de nucleotidos.
AU2014361781B2 (en) 2013-12-12 2021-04-01 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
EP3080259B1 (fr) 2013-12-12 2023-02-01 The Broad Institute, Inc. Ingénierie de systèmes, procédés et compositions guides optimisées avec de nouvelles architectures pour la manipulation de séquences
BR112016013207A2 (pt) 2013-12-12 2017-09-26 Massachusetts Inst Technology administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para o hbv e distúrbios e doenças virais
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
GB201322574D0 (en) 2013-12-19 2014-02-05 Equigerminal Sa Retroviral peptides
EP3082853A2 (fr) 2013-12-20 2016-10-26 The Broad Institute, Inc. Polythérapie comprenant un vaccin à base de néoantigènes
EP3686279B1 (fr) 2014-08-17 2023-01-04 The Broad Institute, Inc. Édition du génome à l'aide de nickases cas9
WO2016049163A2 (fr) 2014-09-24 2016-03-31 The Broad Institute Inc. Utilisation et production d'animaux transgéniques chd8 +/- possédant des phénotypes de comportement caractéristiques d'un trouble du spectre autistique
WO2016049258A2 (fr) 2014-09-25 2016-03-31 The Broad Institute Inc. Criblage fonctionnel avec systèmes crisp-cas fonctionnels optimisés
WO2016069591A2 (fr) 2014-10-27 2016-05-06 The Broad Institute Inc. Compositions, procédés et utilisation de criblage létal synthétique
EP3889260A1 (fr) 2014-12-12 2021-10-06 The Broad Institute, Inc. Arn guides protégés (pgrnas)
WO2016094880A1 (fr) 2014-12-12 2016-06-16 The Broad Institute Inc. Administration, utilisation et applications thérapeutiques de systèmes crispr et compositions pour l'édition de génome de cellules souches hématopoïétiques (hsc)
WO2016094872A1 (fr) 2014-12-12 2016-06-16 The Broad Institute Inc. Guides désactivés pour facteurs de transcription crispr
WO2016094874A1 (fr) 2014-12-12 2016-06-16 The Broad Institute Inc. Guides escortés et fonctionnalisés pour systèmes crispr-cas
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
EP3234192B1 (fr) 2014-12-19 2021-07-14 The Broad Institute, Inc. Identification non biaisée de cassures bicaténaires et réarrangement génomique par séquençage de capture d'insert à l'échelle du génome
WO2016106236A1 (fr) 2014-12-23 2016-06-30 The Broad Institute Inc. Système de ciblage d'arn
WO2016106244A1 (fr) 2014-12-24 2016-06-30 The Broad Institute Inc. Crispr présentant ou associé avec un domaine de déstabilisation
RS63416B1 (sr) * 2015-03-03 2022-08-31 Fond Telethon Sistem višestrukih vektora i njegove primene
WO2016145150A2 (fr) 2015-03-11 2016-09-15 The Broad Institute Inc. Traitement sélectif de cancer dépendant de prmt5
TW202523682A (zh) 2015-05-20 2025-06-16 美商博德研究所有限公司 共有之gata3相關之腫瘤特異性新抗原
WO2016201368A1 (fr) 2015-06-10 2016-12-15 The Broad Institute Inc. Anticorps, composés et écrans permettant l'identification et le traitement la cachexie ou pré-cachexie
TWI813532B (zh) 2015-06-18 2023-09-01 美商博得學院股份有限公司 降低脱靶效應的ｃｒｉｓｐｒ酶突變
WO2016205745A2 (fr) 2015-06-18 2016-12-22 The Broad Institute Inc. Tri cellulaire
EP4159856A1 (fr) 2015-06-18 2023-04-05 The Broad Institute, Inc. Nouvelles enzymes crispr et systèmes
CA3012607A1 (fr) 2015-06-18 2016-12-22 The Broad Institute Inc. Enzymes et systemes crispr
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2017031370A1 (fr) 2015-08-18 2017-02-23 The Broad Institute, Inc. Procédés et compositions permettant de changer la fonction et la structure de boucles et/ou de domaines de chromatine
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
CN109153980B (zh) 2015-10-22 2023-04-14 布罗德研究所有限公司 Vi-b型crispr酶和系统
EP3368687B1 (fr) 2015-10-27 2021-09-29 The Broad Institute, Inc. Compositions et procédés de ciblage de variations de séquences spécifiques du cancer
WO2017075478A2 (fr) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions et méthodes d'évaluation et de modulation des réponses immunitaires à l'aide de signatures génétiques de cellules immunitaires
WO2017075465A1 (fr) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions et procédés d'évaluation et de modulation des réponses immunitaires par détection et ciblage de gata3
WO2017075451A1 (fr) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions et procédés d'évaluation et de modulation des réponses immunitaires par détection et ciblage de pou2af1
WO2017106657A1 (fr) 2015-12-18 2017-06-22 The Broad Institute Inc. Nouvelles enzymes crispr et systèmes associés
EP3446119A1 (fr) 2016-04-18 2019-02-27 The Broad Institute Inc. Prédiction améliorée d'épitope hla
CN110382692A (zh) 2016-04-19 2019-10-25 博德研究所 新型crispr酶以及系统
EP3445853A1 (fr) 2016-04-19 2019-02-27 The Broad Institute, Inc. Complexes cpf1 à activité d'indel réduite
US20200263190A1 (en) 2016-04-19 2020-08-20 The Broad Institute, Inc. Novel crispr enzymes and systems
JP2019519250A (ja) 2016-05-10 2019-07-11 ユナイテッド ステイツ ガバメント アズ リプレゼンテッド バイ ザ デパートメント オブ ベテランズ アフェアーズＵｎｉｔｅｄ Ｓｔａｔｅｓ Ｇｏｖｅｒｎｍｅｎｔ Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｄｅｐａｒｔｍｅｎｔ Ｏｆ Ｖｅｔｅｒａｎｓ Ａｆｆａｉｒｓ Ｈｉｖ−１感染と複製に必須な遺伝子を切断するｃｒｉｓｐｒ／ｃａｓの構築物のレンチウィルスによる送達
CA3028158A1 (fr) 2016-06-17 2017-12-21 The Broad Institute, Inc. Systemes et orthologues crispr de type vi
US12595478B2 (en) 2016-06-29 2026-04-07 The Broad Institute, Inc. Crispr-Cas systems having destabilization domain
CN110312799A (zh) 2016-08-17 2019-10-08 博德研究所 新型crispr酶和系统
WO2018035388A1 (fr) 2016-08-17 2018-02-22 The Broad Institute, Inc. Systèmes et nouvelles enzymes crispr et systèmes
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
WO2018064208A1 (fr) 2016-09-28 2018-04-05 The Broad Institute, Inc. Criblage systématique et cartographie d'éléments régulateurs dans des régions non codantes du génome, ainsi que procédés, compositions et applications associés
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
WO2018140391A1 (fr) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions et procédés de détection d'un variant mutant d'un polynucléotide
ES2950676T3 (es) 2017-01-30 2023-10-11 Kws Saat Se & Co Kgaa Reparación de enlace de plantillas a endonucleasas para modificación de genes
WO2018148671A1 (fr) 2017-02-12 2018-08-16 Neon Therapeutics, Inc. Méthodes et compositions reposant sur le hla et leurs utilisations
AU2018234825B2 (en) 2017-03-15 2020-12-17 Massachusetts Institute Of Technology Novel CAS13B orthologues CRISPR enzymes and systems
AU2018251801B2 (en) 2017-04-12 2024-11-07 Massachusetts Institute Of Technology Novel type VI CRISPR orthologs and systems
US12350368B2 (en) 2017-04-14 2025-07-08 The Broad Institute, Inc. Delivery of large payloads
US11591601B2 (en) 2017-05-05 2023-02-28 The Broad Institute, Inc. Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
EP3625342B1 (fr) 2017-05-18 2022-08-24 The Broad Institute, Inc. Systèmes, procédés et compositions d'édition ciblée d'acides nucléiques
WO2019010422A1 (fr) 2017-07-07 2019-01-10 The Broad Institute, Inc. Thérapie antivirale basée sur le système crispr
CN107502594A (zh) * 2017-07-14 2017-12-22 中国药科大学 一种稳定表达外源性ex－4基因的骨髓源间充质干细胞株
JP2020535802A (ja) 2017-09-21 2020-12-10 ザ・ブロード・インスティテュート・インコーポレイテッド 標的化核酸編集のための系、方法、及び組成物
EP3692152B1 (fr) 2017-10-04 2025-09-03 The Broad Institute, Inc. Procédés et compositions permettant de modifier la fonction et la structure de boucles et/ou de domaines de chromatine
US12227742B2 (en) 2017-10-23 2025-02-18 The Broad Institute, Inc. Nucleic acid modifiers
US11547614B2 (en) 2017-10-31 2023-01-10 The Broad Institute, Inc. Methods and compositions for studying cell evolution
EP3710039A4 (fr) 2017-11-13 2021-08-04 The Broad Institute, Inc. Méthodes et compositions de traitement du cancer par ciblage de la voie clec2d-klrb1
WO2019094984A1 (fr) 2017-11-13 2019-05-16 The Broad Institute, Inc. Procédés de détermination de la dynamique d'expression génique spatiale et temporelle pendant la neurogenèse adulte dans des cellules uniques
WO2019126709A1 (fr) 2017-12-22 2019-06-27 The Broad Institute, Inc. Systèmes cas12b, procédés et compositions pour l'édition de base d'adn ciblée
US10968257B2 (en) 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
US11660353B2 (en) 2018-04-27 2023-05-30 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
CN119410636A (zh) 2018-04-27 2025-02-11 分贝治疗公司 肌球蛋白15启动子及其用途
AU2019269593A1 (en) 2018-05-15 2020-11-26 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
EP3820509A1 (fr) 2018-07-09 2021-05-19 Flagship Pioneering Innovations V, Inc. Compositions de fusosomes et utilisations associées
CN113286884A (zh) 2018-08-07 2021-08-20 博德研究所 新型cas12b酶和系统
WO2020041380A1 (fr) 2018-08-20 2020-02-27 The Broad Institute, Inc. Méthodes et compositions de régulation optochimique de crispr-cas9
WO2020072700A1 (fr) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Lignées d'allèles uniques d'alh
SG11202105079QA (en) 2018-11-14 2021-06-29 Flagship Pioneering Innovations V Inc Fusosome compositions for cns delivery
WO2020102503A2 (fr) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Compositions de fusosome pour administration à des lymphocytes t
EP3880832A1 (fr) 2018-11-14 2021-09-22 Flagship Pioneering Innovations V, Inc. Compositions de fusosomes pour l'apport de cellules souches hématopoïétiques
WO2020131586A2 (fr) 2018-12-17 2020-06-25 The Broad Institute, Inc. Méthodes d'identification de néo-antigènes
CA3124110A1 (fr) 2018-12-17 2020-06-25 The Broad Institute, Inc. Systemes de transposases associes a crispr et procedes d'utilisation correspondants
AU2019404547B2 (en) 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
EP3921032A4 (fr) 2019-02-08 2022-11-30 Decibel Therapeutics, Inc. Compositions et procédés de traitement de la surdité neurosensorielle à l'aide de systèmes à deux vecteurs pour l'otoferline
AU2020218547A1 (en) 2019-02-08 2021-08-26 Decibel Therapeutics, Inc. Myosin 15 promoters and uses thereof
US12215382B2 (en) 2019-03-01 2025-02-04 The General Hospital Corporation Liver protective MARC variants and uses thereof
US20220175962A1 (en) 2019-03-10 2022-06-09 Sio Gene Therapies Inc. Gene therapy compositions and methods for treating parkinson's disease
US12534714B2 (en) 2019-03-18 2026-01-27 The Broad Institute, Inc. Type VII CRISPR proteins and systems
US12390018B2 (en) 2019-05-20 2025-08-19 Shanna Dickinson Convertible crib
WO2020236972A2 (fr) 2019-05-20 2020-11-26 The Broad Institute, Inc. Systèmes de ciblage d'acides nucléiques à constituants multiples autres que de classe i
AU2020333667A1 (en) 2019-08-16 2022-02-24 Massachusetts Institute Of Technology Targeted trans-splicing using CRISPR/Cas13
AU2020341454A1 (en) 2019-09-03 2022-03-10 Sana Biotechnology, Inc. CD24-associated particles and related methods and uses thereof
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
CA3159549A1 (fr) 2019-10-30 2021-05-06 Decibel Therapeutics, Inc. Compositions et methodes de traitement de la surdite neurosensorielle a l'aide de systemes a deux vecteurs pour l'otoferline
JP2023521663A (ja) 2020-03-31 2023-05-25 サナ バイオテクノロジー，インコーポレイテッド 標的化脂質粒子及び組成物ならびにその使用
WO2021236852A1 (fr) 2020-05-20 2021-11-25 Sana Biotechnology, Inc. Méthodes et compositions pour le traitement d'infections virales
US20230303665A1 (en) 2020-08-28 2023-09-28 Sana Biotechnology, Inc. Modified anti-viral binding agents
MX2023007003A (es) 2020-12-14 2023-08-18 Biontech Us Inc Antigenos especificos de tejidos para la inmunoterapia del cancer.
CA3200509A1 (fr) 2020-12-31 2022-07-07 Sonja SCHREPFER Methodes et compositions pour moduler une activite de car-t
EP4274901A1 (fr) 2021-01-11 2023-11-15 Sana Biotechnology, Inc. Utilisation de vecteurs viraux ciblant cd8
EP4326745A4 (fr) * 2021-04-23 2025-11-05 Asimov Inc Systèmes de production stables pour la production de vecteurs lentiviraux
AU2022280957A1 (en) 2021-05-28 2023-11-30 Sana Biotechnology, Inc. Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
KR20240046319A (ko) 2021-07-14 2024-04-08 사나 바이오테크놀로지, 인크. 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
WO2023015217A1 (fr) 2021-08-04 2023-02-09 Sana Biotechnology, Inc. Utilisation de vecteurs viraux ciblant cd4
US20250230511A1 (en) 2021-10-29 2025-07-17 Sana Biotechnology, Inc. Methods and reagents for amplifying viral vector nucleic acid products
GB202117405D0 (en) 2021-12-02 2022-01-19 Univ London Queen Mary Peptide
US20250059560A1 (en) 2021-12-16 2025-02-20 Sana Biotechnology, Inc. Methods and systems of particle production
EP4448775A1 (fr) 2021-12-17 2024-10-23 Sana Biotechnology, Inc. Glycoprotéines de fixation de paramyxoviridae modifiées
US20250059239A1 (en) 2021-12-17 2025-02-20 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
WO2023133595A2 (fr) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
EP4472646A1 (fr) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Vecteurs lentiviraux ciblant cd3 et leurs utilisations
US20250144235A1 (en) 2022-02-02 2025-05-08 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
KR20240155390A (ko) 2022-02-17 2024-10-28 사나 바이오테크놀로지, 인크. 조작된 cd47 단백질 및 이의 용도
WO2023183313A1 (fr) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Cellules d'ingénierie avec un transgène dans un locus b2m ou ciita et compositions et procédés associés
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
CN119562762A (zh) 2022-04-04 2025-03-04 加利福尼亚大学董事会 遗传互补组合物和方法
WO2024015892A1 (fr) 2022-07-13 2024-01-18 The Broad Institute, Inc. Procédés et systèmes faisant intervenir l'immunopeptidome hla-ii pour la découverte d'antigènes
WO2024026377A1 (fr) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Procédés de transduction utilisant un vecteur viral et des inhibiteurs de facteurs de restriction antiviraux
US20260055146A1 (en) 2022-08-24 2026-02-26 Sana Biotechnology, Inc. Delivery of heterologous proteins
US20260098062A1 (en) 2022-09-21 2026-04-09 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024081820A1 (fr) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Particules virales ciblant des cellules souches hématopoïétiques
WO2024119157A1 (fr) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Particules lipidiques avec cofusogènes et leurs procédés de production et d'utilisation
WO2024220597A2 (fr) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Dosage numérique utilisant des gouttelettes pour détecter un vecteur lentiviral compétent pour la réplication
EP4698665A1 (fr) 2023-04-18 2026-02-25 Sana Biotechnology, Inc. Fusogènes de protéine g modifiés et particules lipidiques associées et procédés associés
EP4698666A1 (fr) 2023-04-18 2026-02-25 Sana Biotechnology, Inc. Fusogènes de protéine g universelle et systèmes adaptateurs de ceux-ci et particules lipidiques et utilisations associées
KR20260016952A (ko) 2023-05-23 2026-02-04 사나 바이오테크놀로지, 인크. 탠덤 퓨소젠 및 관련 지질 입자
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
AU2024328949A1 (en) 2023-08-23 2026-03-12 Sana Biotechnology, Inc. Modified cd47 proteins and their uses
WO2025072383A1 (fr) 2023-09-25 2025-04-03 The Broad Institute, Inc. Cadres de lecture ouverts de virus, leurs utilisations et leurs procédés de détection
WO2025097055A2 (fr) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions et méthodes d'utilisation de lymphocytes t en immunothérapie
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
WO2025129158A1 (fr) 2023-12-15 2025-06-19 The Broad Institute, Inc. Vésicules d'administration contenant des polypeptides arc modifiés et leurs utilisations
WO2025184529A1 (fr) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Particules virales à présentation fusogène et compositions et procédés associés
WO2025212519A1 (fr) 2024-04-01 2025-10-09 Moonlight Bio, Inc. Protéines de liaison au dll3 et leurs utilisations
WO2025250808A1 (fr) 2024-05-29 2025-12-04 The Brigham And Women’S Hospital, Inc. Compositions et méthodes d'administration anti-crispr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544771B1 (en) 1987-12-11 2003-04-08 Cell Genesys, Inc. Retroviral gene therapy vectors and therapeutic methods based thereon
US5631162A (en) 1993-06-11 1997-05-20 Massachusetts Institute Of Technology Retroviral vectors for transducing β-globin gene and β-locus control region derivatives
ATE238427T1 (de) 1995-03-09 2003-05-15 Austrian Nordic Biotherapeutic Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie
CA2268353A1 (fr) * 1996-10-10 1998-04-16 Henrik Garoff Vecteurs alphavirus et retrovirus

Also Published As

Publication number Publication date
DE69830798D1 (de) 2005-08-11
JP2001517452A (ja) 2001-10-09
GB9720465D0 (en) 1997-11-26
KR20010052077A (ko) 2001-06-25
US7303910B2 (en) 2007-12-04
NZ503317A (en) 2002-05-31
ATE299189T1 (de) 2005-07-15
CA2304259A1 (fr) 1999-04-01
CN1203183C (zh) 2005-05-25
EP1017837B1 (fr) 2005-07-06
AU9175698A (en) 1999-04-12
DE69830798T2 (de) 2005-12-22
NO20001486D0 (no) 2000-03-22
US20050009186A1 (en) 2005-01-13
EP1017837A1 (fr) 2000-07-12
NO20001486L (no) 2000-05-25
WO1999015683A1 (fr) 1999-04-01
CN1279723A (zh) 2001-01-10
AU750110B2 (en) 2002-07-11
US6808922B1 (en) 2004-10-26
WO1999015683A8 (fr) 1999-05-06

Similar Documents

Publication Publication Date Title
IL134896A0 (en) Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site
PT950386E (pt) Stent com administracao local de rapamicina
AU7364096A (en) Foamable polyester compositions having a low level of unreacted branching agent
EP0730550A4 (fr) Verrouillage d'une plaque de carton
NL350077I1 (nl) Cyprosulfamide
DE69738218D1 (de) Cvd von dünnen fluorkohlenstoffen-polymer-filmen
AU5083596A (en) Elastomers from silicone emulsions having self-catalytic crosslinkers
DE69529729D1 (de) Synthetisierer hoher Präzision sowie niedrigen Phasenrauschens, mit Vektormodulator
FR2733292B1 (fr) Dispositif tendeur de cable
ID19769A (id) Sintase isoprenoid kimerik dan penggunaannya
FR2720640B1 (fr) Compositions cosmétiques photoprotectrices à base d'un mélange synergétique de filtres et de nanopigments et utilisations.
WO1991001027A3 (fr) Detection de sequence interdite et circuit de protection
EP0980903A3 (fr) Composition pour modifier un revêtement antiadhésif
DK0742139T3 (da) Gastankskib
GB2359306A (en) Vector
FR2748318B1 (fr) Dispositif d'injection de plasma
ATE308548T1 (de) Glycerophosphoinositol-derivate als cytosolic a2 phospholipase modulatoren
TR200000738T2 (tr) Difosjenden ve/veya trifosjenden fosjen hazırlanması için yöntem ve gereç.
FR2782421B1 (fr) Dispositif de generation d'une haute tension
GB2344592A (en) Retroviral vectors comprising a functional splice donor site and a funcional splice acceptor site
AU1059797A (en) Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same
GB2362886A (en) Retroviral vectors comprising functional and non-functional splice donor and splice acceptor sites
WO2000001835A3 (fr) Integration ciblee dans des chromosomes au moyen de vecteurs retroviraux
DE69530062D1 (de) "Capsaicinoid" enthaltendes Tränengas
WO1998049998A3 (fr) Utilisation de composes de silicium glycosidiques pour la production de preparations cosmetiques et/ou pharmaceutiques